Their survival, especially for the very youngest patients under the age of 35, may actually not be as good as somebody in their 40s or someone in their 60s, despite receiving more aggressive treatment and being at baseline healthier.
on the new single-cell atlas study
“Novartis now expects to speak with the FDA about a potential accelerated approval of pelabresib before the end of the year, CEO Vas Narasimhan told investors on a call Tuesday.”
“The industry has gotten more consolidated. Prices are higher than ever. Access is worse than ever.”
“The rising costs are unsustainable for individuals, for businesses, and for the country. What kind of intervention is a different question.”